Four things to know:
1. Second quarter sales grew 2.4 percent year-over-year. For the first half of 2023, sales were $625.5 million.
2. NuVasive saw a net income of $7.4 million in the second quarter.
3. Revenue was primarily driven by increased product adoption and increased surgical volumes in the U.S.
4. The company is maintaining its full-year growth projection of 6 percent to 8 percent revenue increases compared to 2022.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
